High HDL may reduce risk of prostate cancer recurrence
the ONA take:
According to a new study published in the journal Cancer Epidemiology, Biomarkers & Prevention, researchers at Duke University School of Medicine in Durham, North Carolina, have found that high cholesterol may be associated with an increased risk for developing prostate cancer.
For the study, the researchers analyzed blood lipid levels from 843 men diagnosed with prostate cancer who had undergone a radical prostatectomy. All men had no history of taking statin medications that lower cholesterol.
Of all samples, 325 men had abnormal cholesterol levels and 263 had abnormal triglyceride levels. In addition, 293 men had elevated prostate-specific antigen (PSA) levels, which indicate that those men experienced a prostate cancer recurrence. Men with triglyceride levels above 150 mg/dL were 35% more likely to experience a prostate cancer recurrence compared with men with normal triglyceride levels under 150 mg/dL.
Furthermore, men with total cholesterol levels over 200 mg/dL had a 9% increased risk for experiencing a prostate cancer recurrence for every 10 mg/dL increase over 200 mg/dL. By contrast, men with high levels of high density lipoprotein (HDL) have a 39% decreased risk of prostate cancer recurrence for every 10 mg/dL increase over 40 mg/dL.
The findings suggest that the risk for prostate cancer recurrence may be lowered by controlling dyslipidemia.
High cholesterol may be associated with an increased risk for developing prostate cancer.
Among men who have surgery for prostate cancer, those who have high total cholesterol and triglyceride levels - two types of fat found in blood - may be at increased risk of disease recurrence. This is according to a study published in the journal Cancer Epidemiology, Biomarkers & Prevention.
After skin cancer, prostate cancer is the most common cancer in American men. This year, 233,000 men will be diagnosed with prostate cancer, and 29,480 will die from it. According to the research team, including Emma Allot, PhD, postdoctoral associate at Duke University School of Medicine in Durham, NC, laboratory studies have linked high cholesterol levels to prostate cancer, but population-based studies looking at this association have been unclear.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Breast Cancer Diagnosis and Nurse Navigation Survey
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
- Radiotherapy is Essential in Treating Brain Tumors But Associated With Significant Adverse Events
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|